A Phase 2 Study to Evaluate the Safety and Immunological Efficacy of Therapeutic Cancer Vaccine (AST-301, pNGVL3-hICD) in Patients With HER2 Expressing Gastric Cancer (CORNERSTONE-003)

Status: Recruiting

Phase of Trial: Phase II

Latest Information Update: 19 Jul 2024

Price :

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

Drugs AST-301 (Primary) ; Granulocyte macrophage colony stimulating factor (Primary)
Indications Gastric cancer
Focus Adverse reactions; Proof of concept; Therapeutic Use
Acronyms Conerstone3
Sponsors Aston Science

10 Jul 2024 Planned primary completion date changed from 15 Oct 2023 to 15 Oct 2025.
18 Jul 2023 Status changed from not yet recruiting to recruiting.
17 Mar 2023 New trial record

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com